MedTrace Logo

QLS4131 Combination Therapy in Malignant Plasma Cell Neoplasms

NCT07560449 · Status: NOT_YET_RECRUITING · Phase: PHASE2 · Type: INTERVENTIONAL · Enrollment: 162

Last updated 2026-05-01

No results posted yet for this study

Summary

The purpose of the study is to compare the efficacy of QLS4131(SC) in combination with QL2109, with or without pomalidomide or lenalidomide, and QLS4131 (SC) in combination with QL2109, and QLS4131 (SC) in combination with Pomalidomide, and QLS4131(SC) in combination with QL2109 and Lenalidomide.

Conditions

  • Malignant Plasma Cell Neoplasms

Interventions

DRUG

QLS4131

QLS4131 will be administered subcutaneously.

DRUG

QL2109

QL2109 will be administered subcutaneously.

DRUG

Pomalidomide

Pomalidomide will be self-administered as a single dose orally.

DRUG

Lenalidomide

Lenalidomide will be self-administered as a single dose orally.

DRUG

Dexamethasone

Dexamethasone will be administered orally or intravenously.

Sponsors & Collaborators

  • Qilu Pharmaceutical Co., Ltd.

    lead INDUSTRY

Study Design

Allocation
NON_RANDOMIZED
Purpose
TREATMENT
Masking
NONE
Model
PARALLEL

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2026-06-30
Primary Completion
2028-06-30
Completion
2030-06-30

More Related Trials

Entities

Drugs

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT07560449 on ClinicalTrials.gov